Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients

References

• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa170183029117498
   PubMed Web of Science ®Google Scholar
• Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J clin oncol. 2016;34(9):927–935. doi:10.1200/JCO.2015.62.350426786933
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.21802721
   PubMed Web of Science ®Google Scholar
• Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753–758. doi:10.1038/396459338790
   PubMed Web of Science ®Google Scholar
• Manavathi B, Dey O, Gajulapalli VNR, Bhatia RS, Bugide S, Kumar R. Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev. 2013;34(1):1–32. doi:10.1210/er.2011-105722947396
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1
   PubMed Web of Science ®Google Scholar
• Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett. 2007;256(1):1–24. doi:10.1016/j.canlet.2007.03.01617475399
   PubMed Web of Science ®Google Scholar
• Haque MM, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne). 2019;10:573. doi:10.3389/fendo.2019.0057331496995
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643. doi:10.1038/nrc271319701242
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J clin oncol. 2010;28(27):4120–4128. doi:10.1200/JCO.2009.25.965520585090
   PubMed Web of Science ®Google Scholar
• Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J clin oncol. 2008;26(4):549–555. doi:10.1200/JCO.2006.10.102218071188
   PubMed Web of Science ®Google Scholar
• Helland T, Hagen KB, Haugstøyl ME, et al. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Res Treat. 2019;177(1):185–195. doi:10.1007/s10549-019-05294-w31144152
   PubMed Web of Science ®Google Scholar
• Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–552. doi:10.1007/s10549-013-2560-823674192
   PubMed Web of Science ®Google Scholar
• Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504. doi:10.20892/j.issn.2095-3941.2016.006628154782
   PubMed Web of Science ®Google Scholar
• Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5):747–754. doi:10.3892/etm.2010.13322993598
   PubMed Web of Science ®Google Scholar
• Gudlaugsson E, Skaland I, Janssen EA, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61(6):1134–1144. doi:10.1111/j.1365-2559.2012.04329.x22963617
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–750. doi:10.1093/jnci/djp08219436038
   PubMed Web of Science ®Google Scholar
• Arima N, Nishimura R, Osako T, et al. Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. Oncol Lett. 2019;17(1):616–622. doi:10.3892/ol.2018.963330655808
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167–170. doi:10.1093/jnci/djk02017228000
   PubMed Web of Science ®Google Scholar
• Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J clin oncol. 2011;29(31):4160–4167. doi:10.1200/JCO.2010.32.961521947828
   PubMed Web of Science ®Google Scholar
• Jirstrom K, Ryden L, Anagnostaki L, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol. 2005;58(11):1135–1142. doi:10.1136/jcp.2005.02718516254100
   PubMed Web of Science ®Google Scholar
• Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014. doi:10.1038/npjbcancer.2016.1428721378
   PubMed Web of Science ®Google Scholar
• NBCG NBCG. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft In: The Norwegian Directorate of Health, editor. Nasjonalt Handlingsprogram Med Retningslinjer for Diagnostikk, Behandling og Oppfølging av Pasienter Med Brystkreft. Vol. 10 The Norwegian Directorate of Health; 2017 Available from: https://nbcgblog.files.wordpress.com/2018/01/nasjonalt_handlingsprog_brystkreft_10-versjon_is-2669.pdf. Accessed 622, 2020.
   Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489–500. doi:10.1093/jnci/djr01021325141
   PubMedGoogle Scholar
• Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445–449. doi:10.2147/CLEP.S9945727822082
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash TL. Modern epidemiology - case-control studies In: Modern Epidemiology. 3 ed ed. Philadelhia PA, USA: Lippincott Williams & Wilkins; 2008:124.
   Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–847. doi:10.1038/nm0798-8449662379
   PubMed Web of Science ®Google Scholar
• Skaland I, Janssen EA, Gudlaugsson E, et al. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat. 2009;114(1):39–45. doi:10.1007/s10549-008-9980-x18373192
   PubMed Web of Science ®Google Scholar
• Gudlaugsson E, Klos J, Skaland I, et al. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T(1)(-)(2)N(0)M(0) breast cancer. Polish J Pathol. 2013;64(1):1–8. doi:10.5114/pjp.2013.34596
   Web of Science ®Google Scholar
• Regan MM, Pagani O, Francis PA, et al. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015;154(2):275–286. doi:10.1007/s10549-015-3612-z26493064
   PubMed Web of Science ®Google Scholar
• Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol (Madr). 2008;47(4):506–524. doi:10.1080/02841860802059259
   PubMed Web of Science ®Google Scholar
• Stalhammar G, Robertson S, Wedlund L, et al. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. Histopathology. 2018;72(6):974–989. doi:10.1111/his.1345229220095
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–1664. doi:10.1093/jnci/djr39321960707
   PubMed Web of Science ®Google Scholar
• Wang M, McLaren S, Jeyathevan R, et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance. Pathology. 2019;51(3):246–252. doi:10.1016/j.pathol.2018.12.41630850279
   PubMed Web of Science ®Google Scholar
• Ribelles N, Perez-Villa L, Jerez JM, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res. 2013;15(5):R98. doi:10.1186/bcr355924148581
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–183. doi:10.1016/S1470-2045(09)70262-120152769
   PubMed Web of Science ®Google Scholar
• Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J clin oncol. 2008;26(34):5569–5575. doi:10.1200/JCO.2008.17.082918981464
   PubMed Web of Science ®Google Scholar
• Elzawahry HM, Saber MM, Mokhtar NM, Zeeneldin AA, Ismail YM, Alieldin NH. Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. J Egypt Natl Canc Inst. 2013;25(4):181–191. doi:10.1016/j.jnci.2013.02.00124207090
   PubMedGoogle Scholar
• Beelen K, Opdam M, Severson T, et al. Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer. 2018;18(1):761. doi:10.1186/s12885-018-4516-130041599
   PubMed Web of Science ®Google Scholar
• Cohen AL, Factor RE, Mooney K, et al. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast. 2017;31:219–223. doi:10.1016/j.breast.2016.11.01627915204
   PubMed Web of Science ®Google Scholar
• Acs B, Pelekanou V, Bai Y, et al. Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Lab Invest. 2019;99(1):107–117. doi:10.1038/s41374-018-0123-730181553
   PubMed Web of Science ®Google Scholar
• Muftah AA, Aleskandarany MA, Al-Kaabi MM, et al. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat. 2017;164(2):341–348. doi:10.1007/s10549-017-4270-028478613
   PubMed Web of Science ®Google Scholar
• Khoury T, Zirpoli G, Cohen SM, et al. Ki-67 expression in breast cancer tissue microarrays: assessing tumor heterogeneity, concordance with full section, and scoring methods. Am J Clin Pathol. 2017;148(2):108–118. doi:10.1093/ajcp/aqx05328898983
   PubMed Web of Science ®Google Scholar
• Tadrous PJ. On the concept of objectivity in digital image analysis in pathology. Pathology. 2010;42(3):207–211. doi:10.3109/0031302100364175820350211
   PubMed Web of Science ®Google Scholar
• Robertson S, Stalhammar G, Darai-Ramqvist E, et al. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. J Clin Pathol. 2018;71(9):787–794. doi:10.1136/jclinpath-2017-20497629588372
   PubMed Web of Science ®Google Scholar
• Raap M, Liessem S, Ruschoff J, et al. Quality assurance trials for Ki67 assessment in pathology. Virchows Archiv. 2017;471(4):501–508. doi:10.1007/s00428-017-2142-y28497316
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–171. doi:10.1016/j.pathol.2016.11.00628065411
   PubMed Web of Science ®Google Scholar